From professional translators, enterprises, web pages and freely available translation repositories.
haittavaikutustaulukko
medicinal product no longer authorised
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
haittavaikutustaulukko – aprepitantti
tabulated list of adverse reactions - aprepitant
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
taulukko 5 haittavaikutustaulukko
table 5 tabulated list of adverse reactions
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
taulukko 2: haittavaikutustaulukko
table 2: tabulated summary of adverse reactions
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
laskimoon annettavan lääkemuodon haittavaikutustaulukko
tabulated list of adverse reactions with the intravenous formulation
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
taulukko 6 trastutsumabiemtansiinihoitoa saaneiden potilaiden haittavaikutustaulukko
table 6 tabulated list of adrs in patients treated with trastuzumab emtansine
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tartuntatauteja koskevat turvallisuustiedot, ks. kohta 4.4. haittavaikutustaulukko
for safety with respect to transmissible agents, see section 4.4. tabulated list of adverse reactions
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tietoa valikoitujen haittavaikutusten hoidosta on myös kohdassa 4.4. haittavaikutustaulukko
for the management of selected adverse reactions please also refer to section 4.4. tabulated list of adverse reactions
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
seuraava haittavaikutustaulukko perustuu markkinoilletulon jälkeiseen spontaaniin haittavaikutusten raportointiin ja siten frekvenssejä ei tiedetä:
in a 4 year clinical trial, the general pattern of adverse event distribution was similar to that reported for the 1 and 2 year studies with the total incidence of gastrointestinal related adverse events occurring in year 1 decreasing year on year over the four year period.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
alla esitetty haittavaikutustaulukko koskee siten kineret-hoitoa sekä nivelreuma- että caps- potilaiden osalta.
the adverse reactions table below therefore applies to kineret treatment both in ra and caps patients.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
merkkejä yliherkkyysreaktioista, allergisista reaktioista, seerumin kalsiumiin kohdistuvista vaikutuksista ja luun mineraalitiheysvasteeseen kohdistuvista vaikutuksista ei havaittu.5 seuraava haittavaikutustaulukko perustuu kauppaantulonjälkeisiin spontaaniraportteihin:
5 diminished after withdrawal of therapy.there was no evidence of hypersensitivity reactions, allergic reactions, effects on serum calcium, or effects on bmd response.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
aikuisilla raportoitujen haittavaikutusten (ks. kohta 4.8, haittavaikutustaulukko) lisäksi seuraavia haittavaikutuksia havaittiin useammin pediatrisilla potilailla: anemia oli yleinen (9,5 %) ja ihon värimuutokset (lisääntynyt pigmentaatio) oli hyvin yleinen (31,8 %) pediatrisilla potilailla.
in addition to the adverse reactions reported in adults (see section 4.8, tabulated summary of adverse reactions), the following adverse reactions were observed more frequently in paediatric patients: anaemia was common (9.5%) and skin discolouration (increased pigmentation) was very common (31.8%) in paediatric patients.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: